Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Up 4.4 %

NASDAQ:TENX opened at $3.33 on Monday. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $61.20. The company has a 50 day moving average price of $3.38 and a 200 day moving average price of $6.20.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). On average, sell-side analysts anticipate that Tenax Therapeutics will post -7.96 earnings per share for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.